GAA
MRNA icon

Green Alpha Advisors’s Moderna MRNA Stock Holding History

Green Alpha Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.36M Sell
33,758
-580
-2% -$30K 1.59% 18
2026
Q1 		$1.74M Buy
34,338
+1,182
+4% +$55.1K 1.72% 18
2025
Q4 		$978K Buy
33,156
+5,015
+18% +$136K 0.9% 31
2025
Q3 		$727K Sell
28,141
-3,130
-10% -$87.3K 0.7% 48
2025
Q2 		$863K Buy
31,271
+2,597
+9% +$68.4K 0.82% 41
2025
Q1 		$813K Buy
28,674
+11,774
+70% +$418K 0.87% 34
2024
Q4 		$703K Buy
16,900
+5,987
+55% +$286K 0.56% 61
2024
Q3 		$729K Buy
10,913
+637
+6% +$58.5K 0.57% 64
2024
Q2 		$1.22M Sell
10,276
-2,676
-21% -$339K 0.98% 33
2024
Q1 		$1.38M Buy
12,952
+1,354
+12% +$136K 1% 32
2023
Q4 		$1.15M Sell
11,598
-133
-1% -$11.2K 0.83% 37
2023
Q3 		$1.21M Buy
11,731
+622
+6% +$69.4K 0.93% 36
2023
Q2 		$1.35M Buy
11,109
+1,311
+13% +$175K 0.89% 41
2023
Q1 		$1.5M Sell
9,798
-741
-7% -$122K 1.06% 28
2022
Q4 		$1.89M Buy
10,539
+1,604
+18% +$262K 1.57% 8
2022
Q3 		$1.06M Sell
8,935
-77,650
-90% -$11.8M 0.9% 35
2022
Q2 		$12.4M Buy
86,585
+78,801
+1,012% +$11.3M 2.84% 8
2022
Q1 		$1.34M Buy
7,784
+721
+10% +$121K 0.9% 42
2021
Q4 		$1.79M Buy
7,063
+326
+5% +$95.3K 1.21% 24
2021
Q3 		$2.59M Sell
6,737
-885
-12% -$326K 1.79% 3
2021
Q2 		$1.79M Sell
7,622
-4,998
-40% -$893K 1.22% 19
2021
Q1 		$1.65M Sell
12,620
-1,944
-13% -$282K 1.64% 14
2020
Q4 		$1.52M Buy
+14,564
New +$1.47M 1.84% 14

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Green Alpha Advisors's MRNA Position: Q2 2026 in Review

Green Alpha Advisors reduced its Moderna (MRNA) stake by 1.7% in Q2 2026, selling an estimated $30K and leaving 33,758 shares worth $2.36M. The position accounts for 1.59% of the portfolio, ranked #18.

Green Alpha Advisors first reported a position in MRNA in Q4 2020 and has held it in 23 quarters since. The position peaked at $12.4M in Q2 2022. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Green Alpha Advisors held 33,758 shares of Moderna worth $2.36M as of Q2 2026.
  • Green Alpha Advisors sold 580 Moderna shares in Q2 2026, an estimated $30K.
  • Moderna made up 1.59% of Green Alpha Advisors's portfolio in Q2 2026, its #18 holding.
  • Green Alpha Advisors first reported a position in Moderna in Q4 2020 and has held it in 23 quarters since.
  • Green Alpha Advisors's Moderna position peaked at $12.4M in Q2 2022.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Green Alpha Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.